Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Early Graft Dysfunction in Adult LDLT
NCT06743464Recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifaximin in primary graft dysfunction (PGD) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Incidence of Early Graft Dysfunction at 9 months. Started Dec 2024; status: recruiting.
02
Drugs
rifaximin
03
Conditions
primary graft dysfunction (PGD)
Beyond the preview
Go deeper on NCT06743464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06743464.